Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will both promote the combination of GalliaPharm^® and Illuccix^® to national radiopharmacy networks, commercial and hospital-based nuclear pharmacies, and other target institutions.

"After previously being granted distribution rights for Germany, our home market, the latest collaboration marks another important milestone for our ⁶⁸Ga generator GalliaPharm^® and our nuclear medicine activities”, explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. “We are pleased to have Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in the USA.”

“This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out ⁶⁸Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art imaging modality and facilitate coast-to-coast access for US men living with prostate cancer.”, added Telix Americas President Dr Bernard Lambert.

Following regulatory approval, Illuccix^® will be offered as a cold kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix^® enables PSMA-11 to be radio-labelled with the radionuclide ⁶⁸Ga directly before injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, sites exhibiting prostate cancer are localized and imaged via the presence of the prostate-specific membrane antigen.^[1],[2]

Prostate cancer is the most common type of cancer in men in the United States, with approximately 210,000 cases in 2020, a significantly higher incidence than either lung cancer (116,000 new cases) or bowel cancer (82,000 new cases).^[3] Prostate cancer was also the second most common cause of cancer death in men, with over 32,000 men dying from the disease in the United States in 2020. More than 812,000 American men were estimated to be living with prostate cancer in 2020.

[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863.
[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216.
[3] IARC Global Cancer Observatory, 2020.

About Telix Pharmaceuticals
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

About Illuccix^®
Telix’s lead investigational product, Illuccix^® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix^® in the European Union and Canada. None of Telix’s products have received a marketing authorisation in any jurisdiction.